Orchard Therapeutics Outlines U.S. Launch Plans For Lenmeldy

Orchard Therapeutics announced the U.S. Food and Drug Administration has approved Lenmeldy™, formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile —collectively referred to as early-onset—metachromatic leukodystrophy.